Sanofi, Regeneron to Continue Trial of Cholesterol Drug Praluent
November 17 2016 - 2:57AM
Dow Jones News
PARIS--Drug makers Sanofi and Regeneron Pharmaceuticals Inc.
Thursday said they will continue trials of cholesterol-lowering
medicine Praluent after interim analysis.
The trial will continue as planned, based on the recommendation
of an independent data-monitoring committee, the companies
said.
Sanofi is betting on new drugs such as Praluent, a new class of
cholesterol-lowering medicine, to help boost its revenue as its
diabetes drug sales come under pressure.
Praluent is currently approved in approximately 40 countries
worldwide, including the U.S., Japan, Canada, Switzerland, Mexico,
Brazil and the European Union.
The Phase 3, multi-center, randomized, double-blind,
placebo-controlled trial involves more than 18,000 patients from 57
countries, the drug makers said.
Write to William Horobin at william.horobin@wsj.com
(END) Dow Jones Newswires
November 17, 2016 02:42 ET (07:42 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
